Prospective validation of serum CYFRA 21-1, β-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy

Cancer

Volumn 101, Issue 4, 2004, Pages 776-781

  Ma, Brigette B Y ^a,b   Leungm, Sing F ^a   Hui, Edwin P ^b   Mo, Frankie ^a   Kwan, Wing H ^b   Zee, Benny ^a   Yuen, Joyce ^b   Chan, Anthony T C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

2 microglobulin; CYFRA 21 1; Ferritin; Nasopharyngeal carcinoma

Indexed keywords

BETA 2 MICROGLOBULIN; CYTOKERATIN 19 FRAGMENT; FERRITIN; TUMOR MARKER; VIRUS DNA;

ADULT; AGE DETERMINATION; AGED; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EPSTEIN BARR VIRUS; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NASOPHARYNX CARCINOMA; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SURVIVAL RATE; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BETA 2-MICROGLOBULIN; CARCINOMA; DNA, VIRAL; FEMALE; FERRITINS; HERPESVIRUS 4, HUMAN; HUMANS; KERATINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 3543147149     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20430     Document Type: Article

References (35)

1. Teo PM, Chan AT. Nasopharyngeal cancer - treatment strategy and clinical experience. Semin Cancer Biol. 2002;12:497-504.
2. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1528 patients from six randomized trials. Am J Clin Oncol. 2002;25:219-223.
3. Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001;345:1877-1882.
4. Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002; 94:1614-1619.
5. Chan KC, Lo YM. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12: 489-496.
6. Leung SF, Lo YM, Chan AT, et al. Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2. Clin Cancer Res. 2003;9:3431-3434.
7. Lin JC, Chen KY, Wang WY, et al. Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol. 2001;19:2607-2615.
8. Ho S, Leung SF, Leung WT, et al. Strong association between hyperferritinaemia and metastatic disease in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol. 1996;32B:242-245.
9. Ho S, Leung WT, Yuen J, et al. Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy. Eur J Cancer B Oral Oncol. 1996;32B:377-380.
10. Shiu W, Leung SF, Leung WT, et al. Expression of beta-2-microglobulin by nasopharyngeal carcinoma. Br J Cancer. 1992;66:555-557.
11. Karnak D, Ulubay G, Kayacan O, et al. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas. Lung. 2001;179:57-65.
12. Kulpa J, Wojcik E, Reinfuss M, et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem. 2002;48:1931-1937.
13. Walsh TN, Grannell M, Mansoor S. Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer. J Gastroenterol Hepatol. 2002;17(Suppl):S172-S175.
14. Gadducci A, Ferdeghini M, Cosio S, et al. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer. 2001;11:277-282.
15. Pras E, Willemse PH, Canrinus AA, et al. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int J Radiat Oncol Biol Phys. 2002;52:23-32.
16. Doweck I, Barak M, Uri N, et al. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer. 2000;83:1696-1701.
17. Lin WY, Yen TC, Cheng KY, et al. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma. Neoplasma. 1998;45:21-24.
18. Yen TC, Lin WY, Kao CH, et al. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol. 1998;23:82-86.
19. Lee JK, Hsieh JF, Tsai SC, et al. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 2001;110:775-778.
20. Tai CJ, Liu FY, Liang JA, et al. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma. Anticancer Res. 2002;22:3793-3796.
21. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a Phase III randomized trial. J Clin Oncol. 2002;20:2038-2044.
22. Reinmuth N, Brandt B, Semik M, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer. 2002;36:265-270.
23. Doweck I, Barak M, Greenberg E, et al. Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg. 1995;12: 177-181.
24. Vollmer RT, Govindan R, Graziano SL, et al. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res. 2003;9:1728-1733.
25. Pujol JL, Daures JP, Daver A, et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993; 53:61-66.
26. Kuropkat C, Lippert BM, Werner JA. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck. Oncology. 2002;63:280-285.
27. Niklinski J, Chyczewska E, Chyczewski L, et al. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. Eur Respir J. 1995;8:291-294.
28. Hoffmann-Fazel A, Gottschlich S, Maass JD, et al. Cyfra 21-1 in diagnosis of distant metastases of head and neck carcinoma. Anticancer Res. 2003;23:917-920.
29. Banal A, Hacene K, Berthelot-Ruff E, et al. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours. Tumour Biol. 2001;22:27-35.
30. Maass JD, Hoffmann-Fazel A, Goeroegh T, et al. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer. Anticancer Res. 2000;20:2241-2243.
31. Deng YF, Lin YZ, Le JZ, et al. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol. 2003;117:190-194.
32. Niemann AM, Goeroegh T, Gottschlich S, et al. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Anticancer Res. 1997;17: 2859-2860.
33. Au JS, Foo W, Lau WH. In-depth evaluation of the AJCC/UICC 1997 staging system of nasopharyngeal carcinoma: prognostic homogeneity and proposed refinements. Int J Radiat Oncol Biol Phys. 2003;56:413-426.
34. Fandi A, Bachouchi M, Azli N, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol. 2000;18:1324-1330.
35. Philip B. Real-time PCR technology for cancer diagnostics. Clin Chem. 2002;48:1178-1185.